Samsung Bioepis Co Ltd, a joint venture between Samsung BioLogics and US-based Biogen (Nasdaq: BIIB), yesterday announced the European launch of IMRALDITM, an adalimumab biosimilar referencing Humira(R).

IMRALDI is approved in Europe for the treatment of rheumatoid arthritis (RA), juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, paediatric plaque psoriasis, adult and adolescent hidradenitis suppurativa, Crohn's disease, paediatric Crohn's disease, ulcerative colitis and uveitis.

Ian Henshaw, global head of Biosimilars at Biogen, said, 'We are proud to be pioneering innovation in biosimilars to help transform the lives of people in Europe with chronic autoimmune conditions. With the addition of IMRALDI to our anti-TNF biosimilar offering, we are increasing physician choice and patient access in Europe to affordable treatments across disease areas.'